PAVmed 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Lucid began submitting Medicare claims for Easi-Guard through its Texas laboratory in late September and has been paid consistently since October at the full Medicare rate; October was a record month for test volume.
- Verus enrollment at Ohio State nearly doubled from July to September, and the clinical rollout is live across most departments at the James Cancer Center.
- Verus achieved design freeze for its implantable physiologic monitor in August and initiated a 90-day GLP animal study in October.
- The Octerus next-generation probe is complete and ready for clinical testing, while the PortIO team held an initial call with the FDA in late October.
- PAVmed reported preliminary cash of $8.9 million at September 30th, including $5.3 million of restricted cash, and an underlying 3rd quarter burn of approximately $2.8 million.
- PAVmed received $2.8 million from its ATM during the quarter and established a new at-the-market facility with AGP for up to $9.4 million, presently fully available.
- The preliminary GAAP net loss was $13 million before non-controlling interest and preferred dividends, compared with a prior-year loss of $6 million; the preliminary GAAP net loss attributable to PAVmed common stockholders was $11.8 million.
- The preliminary non-GAAP loss was $1.2 million, an improvement from $1.7 million in the 2nd quarter; 3rd quarter non-GAAP OpEx was $5.6 million, about $480,000 below the 2nd quarter.
- A non-cash net charge of approximately $9.6 million from changes in fair value of Lucid shares and the senior note was the main driver of the year-over-year increase in the quarterly GAAP loss.
- PAVmed’s $15 million senior secured note carries a 15% interest rate and matures in February of '29; PAVmed did not satisfy its collateral coverage covenant as of September 30th, and the note holder agreed to waive that covenant through the date of the SEC filing.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the PAVmed third quarter 2026 business update conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star 0 for the operator. Please note, this event is being recorded. I would now like to turn the conference over to Matt Riley, PAVmed Vice President of Investor Relations.
Please go ahead, sir. Thank you, operator, and good morning, everyone.
Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and Chief Executive Officer of PAVmed, along with Dennis McGrath, Chief Financial Officer of PAVmed. The press release announcing our business update and financial results is available on PAVmed's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update, press release, and conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the SEC.
For a list and a description of these and other important risks and uncertainties that may affect future operations, see Part 1, Item 1A, entitled Risk Factors in PAVmed's most recent annual report on Forms 10-K filed with the SEC, and any subsequent updates filed in quarter reports on Forms 10-Q and subsequent Forms 8-K. Except as required by law, PAVmed disclaims any intentions or obligations to publicly update or revise any forward-looking statements to reflect changes in expectations or in events, conditions, or circumstances on which the expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. I would now like to turn the call over to Dr. Lishan Aklog, Chairman and CEO of PAVmed.
Thank you, Matt, and good morning, everyone. Thank you for joining our quarterly update call. We're very encouraged by developments across our PAVmed portfolio. The most important development, of course, is that Lucid has secured Medicare reimbursement for EsoGuard, and this is a critical and transformational milestone. On the other front, Veris continues to grow enrollment at Ohio State while advancing its implantable monitor towards FDA submission, and we are now actively engaged with the FDA on our two other portfolio units, PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value. Let me start with Lucid. The most significant development at Lucid is that Medicare is now reimbursing EsoGuard. Lucid began submitting claims through its Texas laboratory in late September and has been paid consistently since October at the full Medicare rate.
The engagement with the contractor and subsequent consistent pattern constitutes Medicare coverage through claim-by-claim adjudication, and this applies for two Medicare patients nationwide. With Medicare reimbursement now secured, Lucid immediately and aggressively transitioned its commercial activity to focus on access to EsoGuard in the Medicare population. This transition is going extremely well, and October was a record month for test volume. We expect to quickly scale Lucid's commercial activity to take advantage of its massive revenue opportunity and to grow its commercial infrastructure in an aggressive but responsible way. As Lucid's largest shareholder, PAVmed stands to benefit directly from this near-term opportunity. Yesterday's Lucid call covers this and other developments in far greater detail, and I encourage you to listen to the recording. Now let's move on to Veris. The commercial phase of our Ohio State strategic engagement continues to accelerate.
Monthly enrollment grew throughout the quarter and nearly doubled from July to September, and the clinical rollout is now live across most of the departments at the James Cancer Center, with the remaining departments moving through the final implementation stage. Our focus remains reducing onboarding friction and workflow disruption, and we continue to have strong support from the OSU and the James leadership team. We have also continued to improve the software platform, including an upgraded EHR integration and various software updates. The implantable physiological monitor remains on track for an FDA 510(k) submission in early 2027. We successfully achieved design freeze in August as planned, and in October, we initiated the 90-day GLP animal study, which is a key part of the verification and validation testing required for FDA 510(k) submission.
We expect to complete the app design freeze and the skin validation study, both additional components of the FDA submission, by the year end. Now let's move on to our other products in our medical device portfolio, starting with PortIO. As a reminder, PortIO is an implantable intraosseous port that is designed to provide long-term vascular access through the bone marrow cavity, and particularly for patients with difficult or compromised venous access. We held an initial call with the FDA in late October. It was successful, and this will be followed by an in-person pre-submission meeting, a formal pre-submission meeting in January. The key topic will be the regulatory pathway. We believe that our published first-in-human results may support a 510(k) rather than a De Novo regulatory pathway through the FDA. That would mean a shorter timeline and lower capital requirements to reach commercialization. Now let's finish up with Octeris.
Again, as a reminder, Octeris is our multimodal endoscopic imaging platform that we licensed from Duke University, and it is designed to identify esophageal dysplasia, or late-stage pre-cancer, during upper endoscopy and to help guide more accurate biopsy and treatment. The next-generation probe is now complete and ready for clinical testing. We expect to submit our initial FDA pre-submission package this month. The start of the clinical validation study at the University of North Carolina is in the IRB phase and going through contracting at the two universities. We expect enrollment to begin in January. With that, I will hand the call over to Dennis for an update on our financials.
Thanks, Lishan, and good morning, everyone. Our preliminary financial results for the third quarter were reported in our press release that has been distributed. On the next three slides, I will emphasize a few highlights from the third quarter, but encourage you to consider those remarks in the context of the full disclosures that will be covered in our quarterly report on Form 10-Q, expected to be filed with the SEC on Monday. With regard to the balance sheet, a few key items to point out. Cash at September 30th was $8.9 million, including $5.3 million of restricted cash. Of the restricted cash, $5 million is held in a collateral account as additional security for the senior debt, which we funded in August under an amendment to the note. During the quarter, we received $2.8 million of proceeds from our ATM, which is timed with the maximum allowable under the ATM.
In September, we put in place a new at-the-market facility with A.G.P. for up to $9.4 million, which is presently fully available to us. Our underlying burn for the third quarter was approximately $2.8 million compared with $2.7 million in the second quarter. Cash on the balance sheet also does not reflect the $30 million expected upon exercise of the Series D warrants, which are currently out of the money, but potentially callable in the future by the company, nor the approximately $2.5 million of Veris warrants that become callable upon FDA clearance of the Veris implantable device. The equity method investment balance of $23.5 million reflects the 31.3 million Lucid shares marked to market at Lucid's closing price of $0.75 on September 30th, down from $1.07 at June 30th.
That $10 million decrease is a non-cash mark-to-market adjustment and is the single largest item in our third quarter P&L, which I will come back to. At present, PAVmed continues to be the single largest common shareholder of Lucid, with approximately 15% of the common shares outstanding. Although PAVmed no longer has voting control of Lucid, PAVmed, together with its board and management, still has significant influence over Lucid, with approximately 25% of voting interest. Shares outstanding today, including unvested RSAs, are approximately 8 million. The GAAP quarter-end outstanding shares of 6.9 are reflected on the slide as well as it will be on the face of the balance sheet in the 10-Q. GAAP shares do not reflect unvested RSA amounts. A word on our $15 million senior secured note, which carries a 15% interest rate, is interest only with quarterly payments and matures in February of 2029.
The note includes financial covenants, one of which is a minimum cash covenant, which we satisfied at September 30th. Another is a collateral coverage covenant tied to the market value of the Lucid shares we hold. With the decline in Lucid share price during the quarter, we did not satisfy that collateral coverage covenant as of September 30th. The note holder has agreed to waive that covenant through the date of our SEC filing, and we continue to work constructively with the note holder as we have consistently in the past on covenants going forward. The details will be in note nine of the financial statements in our 10-Q. The note is required to be carried at fair value. At September 30th, the preliminary value reflects $14.2 million compared with $15.1 million at June 30th, after the $600,000 quarterly interest payment.
The resulting $300,000 gain in the P&L is a non-cash accounting item, and both of these do not change the $15 million principal we owe. These non-cash amounts are subject to change as we complete the final valuation analysis prior to the filing of the 10-Q. Obviously, like others, the Microsoft outage yesterday slowed down the completion of that effort. Similar to past presentations, on this slide of the P&L, it provides some GAAP and non-GAAP year-over-year quarterly comparisons. On a pro forma basis and purely for illustrative purposes on this slide, the Veris revenue and the Lucid management fee income are combined, collectively more than $3 million per quarter, just to visually align PAVmed's income sources versus its operating expenses. For SEC reporting purposes, the management service income is a below-the-line item.
For the third quarter, you will see on the slide a preliminary GAAP net loss of $13 million before non-controlling interest and preferred dividends, versus the prior year loss of $6 million. The driving force of that difference is the change in fair value of the Lucid shares and the senior note, both non-cash amounts, reflecting a net charge of approximately $9.6 million in the current quarter compared with $4.5 million in the prior year quarter. Other than the fair value changes, the most significant change between the periods is higher R&D expense, largely for the Veris implantable device. The preliminary GAAP net loss attributable to PAVmed common stockholders is $11.8 million for the third quarter, and that is subject to the final debt valuation analysis. On a non-GAAP basis, the loss is $1.2 million, an improvement from $1.7 million in the second quarter. Next slide, please. With regard to the non-GAAP operating expenses, on this slide, you will see a graphic illustration of our operating expenses over time as presented in more detail in our press release.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
